D-Penicillamine and fatal obliterative bronchiolitis.
Stuart Campbell,M. Whitehead
DOI: https://doi.org/10.1136/bmj.1.6053.105-a
1977-01-08
British Medical Journal
Abstract:Of 64 patients with severe menopausal symptoms who were allocated to a four-month trial in which Premarin and placebo were each taken for two months, 44 had severe vasomotor symptoms; a further 56 patients with less severe symptoms were allocated to a longer, 12 month trial in which Premarin and placebo were each taken for six months. It is stressed that neither the patients nor the attending doctors knew which treatment was being given. Graphic rating scales,' I which are a widely accepted and sensitive method of measuring change, were used to assess the effects of therapy, and thus the argument that a flush count is not an objective way of evaluating therapy cannot apply to these trials. During placebo therapy, with respect to control values, there was a small, nonsignificant reduction in hot flushes in patients on the four-month trial, and in patients on the 12-month trial this reduction was just statistically significant (P < 005). However, during oestrogen therapy, with respect to placebo values, there was a statistically significant reduction in hot flushes in patients on both the four-month (P < 0001) and 12month (P < 0 001) trials. Furthermore, in the 64 patients on the fourmonth trial benefits of oestrogen therapy over placebo were observed for 11 additional symptoms. The improvement in such a large number of symptoms is to some extent a domino effect-that is, a reduction in vasomotor symptoms creates a favourable response in a large number of associated symptoms. This could be demonstrated by studying the 20 patients who had severe menopausal symptoms but no hot flushes; in this group significant improvements on oestrogen therapy were observed for only five (vaginal dryness, memory, anxiety, worry about self, and worry about age) of the 11 additional symptoms. However, the improvement in memory and anxiety in this subgroup suggests that the "mental tonic" effect of oestrogens described by Utian5 is an entity and is independent of vasomotor symptoms. The dearth of good placebo studies on the evaluation of oestrogen therapy in the treatment of the menopausal syndrome initiated these trials. Our results indicate that a significant reduction in hot flushes and a significant improvement in wellbeing, both psychological and symptomatic, will be achieved by oestrogen therapy. STUART CAMPBELL M WHITEHEAD